Recall of Critical Emergency Medication
American Regent has initiated a nationwide voluntary recall for three specific lots of Epinephrine Injection, USP 30 mg/30 mL vials. This action follows reports of leaking and cracked containers that failed to maintain proper sterility. The U.S. Food and Drug Administration confirmed the announcement on Thursday, noting that the compromised packaging poses significant health risks to patients requiring emergency intervention for allergic reactions or septic shock.
The investigation into these defects uncovered more than just exterior damage. Testing revealed the presence of particulate matter within the vials. These particles consist of nylon, glass, acrylic, polyethylene, and cellulosic materials. Because this drug is intended for intravenous administration during life-threatening events, the discovery of foreign debris represents a critical safety failure.
Health Risks and Clinical Implications
Injecting a substance contaminated with particulate matter presents a range of severe clinical dangers. The company stated that such particles can block or clot blood vessels, potentially restricting blood flow to vital organs. This could trigger a pulmonary embolism, permanent organ injury, or even death. Patients receiving these injections might also suffer from localized vein irritation, inflammatory responses, or the aggravation of existing infections.
Epinephrine serves as a primary treatment for Type I allergic reactions, including anaphylaxis triggered by drugs, food, or insect bites. It also acts as a vasopressor for adults suffering from hypotension linked to septic shock. Given that these patients are often already in fragile health, the loss of sterility in the medication compounds their medical vulnerability. American Regent confirmed that as of September 3, 2026, no adverse events had been documented, but the potential remains significant.
Affected Lots and Procedures for Recovery
The recalled products share the NDC number 0517-3030-01. Three specific lots are impacted by this recall: 25128L1C0, 25280L1C0, and 26108L1C0. Lot 25128L1C0 carries an expiration date of August 2026 and saw distribution between September 2025 and December 2025. Lot 25280L1C0 expires in October 2026 and was distributed from December 2025 through April 2026. The final affected lot, 26108L1C0, is marked for expiry in July 2027, with distribution occurring from June 2026 to July 31, 2026.
Patients currently in possession of these vials should cease use immediately and consult their healthcare provider. American Regent is currently reaching out to distributors and medical facilities to coordinate the return or replacement of the inventory. The firm provides direct support lines for medical information and product complaints, directing clinicians and patients to report any potential adverse reactions through their pharmacovigilance department. This recall reminds healthcare facilities to verify current inventory against manufacturer safety notices regularly.